The results were consistent with prior studies suggesting that the reductions in virological failure and HIVDR may be partly attributable to improvements in treatment and care, such as replacement of DDI with 3TC as the first-line treatment in NFATP,[1] changes of social demographic factors among patients,[16,17,19–21] and providing high-quality care to HIV/AIDS patients.[19]. This evidence concerns the gene NFATC2 and AIDS.